Diabetologie und Stoffwechsel 2022; 17(S 01): S23
DOI: 10.1055/s-0042-1746272
Abstracts | DDG
02. Poster

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 12-month data analysis

Authors

  • Bruno Guerci

    1   University Hospital of Nancy, Endocrinology - Diabetes - Nutrition, Vandoeuvre Lès Nancy, France

  • Francesco Giorgino

    2   University of Bari Aldo Moro, Department of Emergency and Organ Transplantation, Bari, Italy

  • Luis-Emilio García-Pérez

    3   Lilly, S.A., -, Alcobendas, Spain

  • Kristina Boye

    4   Eli Lilly and Company, -, Indianapolis, United States

  • Kirsi Norrbacka

    5   Eli Lilly Finland, -, Helsinki, Finland

  • Helene Sapin

    6   Lilly France SAS, -, Neuilly-sur-Seine, France

  • Elke Heitmann

    7   Lilly Deutschland GmbH, -, Bad Homburg, Germany

  • Jeremie Lebrec

    8   HaaPACS GmbH, -, Schriesheim, Germany

  • Anne Dib

    6   Lilly France SAS, -, Neuilly-sur-Seine, France

  • Marco Orsini Federici

    9   Eli Lilly Italia SpA, -, Sesto Fiorentino, Italy

  • Martin Füchtenbusch

    10   Diabeteszentrum am Marienplatz, -, München, Germany
Further Information
Also available at
 
 

    Background TROPHIES is a 24-month, prospective, non-comparative, observational study in adult patients with T2D initiating their first injectable glucose-lowering treatment with once-weekly dulaglutide (DU) or once-daily liraglutide (LIRA) in France, Germany, and Italy.

    Methods Patient disposition,clinical characteristics and initial GLP-1 RA (DU and LIRA) persistence were assessed at 12-months. Persistence, defined as no discontinuation of the GLP-1 RA regardless of additions or stops of medication or treatment intensification, was determined by Kaplan-Meier (KM) analysis.

    Results In total, 1112 DU and 1039 LIRA patients were eligible for analysis. The 12-month mean (SD) HbA1c change from baseline was -1.2 (1.4)% (baseline, 8.2 [1.2]%) in the DU cohort and -1.2 (1.5)% (baseline, 8.3 [1.3]%) in the LIRA cohort. At 12-months, 35% DU and 29% LIRA patients reached their individualized HbA1c target set by the physician at baseline. Mean weight change for DU and LIRA from baseline to 12-months was -3.3 (5.5)kg and -3.4 (6.1)kg, respectively. KM probability (95%CI) of initial GLP-1 RA persistence was high in both DU and LIRA cohorts at 12-months: DU0.88 (0.86-0.90); LIRA 0.82 (0.79-0.84).

    Conclusion These data show similar HbA1c and weight reductions for DU and LIRA at 12-months with good persistence, consistent with known clinical trial results.


     

    Conflict of Interest

    1. Bruno Guerci 1) provides research support for Medtronic; Vitalaire; Sanofi; Eli Lilly; Novo Nordisk; 2) is a Clinical investigator for Sanofi; Eli Lilly; NovoNordisk; GSK; BMS; AstraZeneca; Medtronic; Abbott; Roche Diagnostics; MSD; Novartis; Janssen; Boehringer Ingelheim and 3) on the advisory boards for Sanofi; Eli Lilly; NovoNordisk; Novartis; GSK; MSD; Boehringer Ingelheim; AstraZeneca; Abbott; Medtronic; Roche Diagnostics; Francesco Giorgino 1) receives research support for Eli Lilly; Lifescan, Takeda; 2) is a consultant for Boehringer Ingelheim; Lifescan; Merck Sharp & Dohme; Sanofi; AstraZeneca; Medimmune; Roche Diabetes Care; and 3) on the advisory boards for AstraZeneca; Eli Lilly; Novo Nordisk; Roche Diabetes Care; and Sanofi; Luis-Emilio García-Pérez, Kristina Boye, Hélène Sapin, Elke Heitmann, Anne Dib, and Marco Orsini Federici are full-time employees and shareholders of Eli Lilly and Company ; Kirsi Norrbacka is a former employee of Eli Lilly; Jeremie Lebrec is a consultant for Eli Lilly.

    2. This study was initially presented at American Diabetes Association – 81st Annual Scientific Sessions; Virtual; 25-29 June 2021.

    Publication History

    Article published online:
    26 May 2022

    © 2022. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany